EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of adjuvant Endoxan therapy in curative resected patients with stomach cancer


, : Evaluation of adjuvant Endoxan therapy in curative resected patients with stomach cancer. Nihon Gan Chiryo Gakkai Shi 20(1): 114-121

The effect of Endoxan (EX) therapy was evaluated and its interaction with some prognostic factors, based on the data of 213 stomach cancer patients with curative resection who were followed up in Kagawa Prefectural Central Hospital [Japan]. Those patients accounted for 30% of Stomach Cancer Postoperative Study Group1. The profiles were examined of the patients for whom the EX therapy was particularly effective. As a consequence, serosal invasion(s) and lymph node involvement(n) were emerged as the most influential factors on the prognosis and the EX therapy was effective for patients with symptoms s(-)n(-) and s(+)n(+). In other words, further short-term adjuvant therapy was particularly effective for s(-)n(-) whereas long-term one was effective for s(+)n(+).


Accession: 005395956

PMID: 3998566

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Zhang, L.; Ou, W.; Liu, Q.; Li, N.; Liu, L.; Wang, S., 2014: Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer. Cisplatin-based adjuvant chemotherapy provided a significant advantage in the overall survival (OS) of patients with stage II and III non-small cell lung cancer (NSCLC). However, the compliance and toxicity in cisplatin-based treatment were not al...

L.Z.ang; W.O.; Q.L.u; N.L.; L.L.u; S.W.ng, 2013: Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer. Cisplatin-based adjuvant chemotherapy brought about a significant advantage in overall survival (OS) in patients with stage II and III non-small cell lung cancer(NSCLC). However, the compliance and toxicity in cisplatin-based treatment were not al...

Ogawa, Y.; Aono, T.; Yamada, T.; Nishikawa, K.; Ikeda, K.; Tokunaga, S.; Okawa, K.; Ikehara, T., 2010: Evaluation of liaison-clinical pathway for patients with breast cancer undergoing adjuvant therapy after curative operation--data from questionnaire survey of 56 clinics and 105 patients. To evaluate the liaison-clinical pathway for patients with breast cancer introduced since May 2008, the data from a questionnaires survey of 56 clinics and 105 patients were reviewed. Half of the clinics specialized in internal medicine. 93% of ph...

Yamaguchi, A.; Isogai, M.; Hori, A.; Kawai, M.; Yamaguchi, R.; Kubota, T.; Yamada, T.; Maeda, A., 1996: Administration and dosage of fluorouracil (5-FU) continuous i.v. infusion in patients with non-curative resected/non-resected gastric cancer. This study was conducted to establish the optimum postoperative adjuvant chemotherapy with 5-FU in patients with gastric cancer. Seventy gastric cancer patients were treated after surgery with one of the following regimens; 5-FU 10 mg/kg/24 hrs c....

Secord, A.Alvarez.; Geller, M.A.; Broadwater, G.; Holloway, R.; Shuler, K.; Dao, N-Y.; Gehrig, P.A.; O'Malley, D.M.; Finkler, N.; Havrilesky, L.J., 2013: A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. To determine if there is an advantage to combination chemotherapy and radiation for optimally resected stage IIIC endometrial cancer (EC). A multicenter retrospective analysis of patients with EC from 1991 to 2008 was conducted. Inclusion criteria...

Asakura H., 1970: Cancer chemo therapy by simultaneous administration of thio inosine 5 fluoro uracil endoxan and mitomycin c as an adjuvant therapy of radio therapy. Japan Society For Cancer Therapy The Journal Of Japan Society For Cancer Therapy English Abstracts Of Proceeding Of The Eighth Congress Of The Japan Society For Cancer Therapy Osaka Oct 19, 20, 117 P Japan Society For Cancer Therapy: Department Of Surgery, School Of Medicine, Kyoto University, Sakyoku, Kyoto, Japan 77-79

Lim, K-Hyoung.; Oh, D-Youn.; Chie, E.Kyu.; Jang, J-Young.; Im, S-Ah.; Kim, T-You.; Kim, S-Whe.; Ha, S.Whan.; Bang, Y-Jue., 2010: Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study. There is currently no standard adjuvant therapy for patients with curatively resected extrahepatic biliary tract cancer (EHBTC). The aim of this study was to analyze the clinical features and outcomes between patients undergoing adjuvant concurren...

Schwarz, R.E., 2001: Postoperative adjuvant chemoradiation therapy for patients with resected gastric cancer: intergroup 116. Journal of Clinical Oncology 19(6): 1879-1880

Bernier, J.; Vermorken, J.B.; Koch, W.M., 2006: Adjuvant therapy in patients with resected poor-risk head and neck cancer. In patients with locally or regionally advanced head and neck carcinomas, postoperative radiotherapy has historically been the adjuvant therapy applied for patients with prognostically worrisome pathologic features. Any improvement in therapeutic...

Zhang, W.; Zhao, G.; Wei, K.; Zhang, Q.; Ma, W.; Wu, Q.; Zhang, T.; Kong, D.; Li, Q.; Song, T., 2016: Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors. Currently there is no predictor for survival after adjuvant sorafenib in patients with hepatocellular carcinoma (HCC) who have undergone curative resection. Thirty-eight patients who underwent curative resection of HCC received adjuvant sorafenib...